However, microdosing semaglutide remains off-label and is not endorsed by the manufacturer (Novo Nordisk) or organizations like the American Diabetes Association, as no dedicated clinical trials have validated its long-term safety or efficacy
The gastrointestinal adverse events associated with GLP-1 receptor agonists are typically dose-dependent, transient, and manageable with slow titration (Meier, Diabetes, Obesity and Metabolism )
Steinert, S
HbA1c staying above target despite metformin Overweight or obesity, especially the abdominal fat pattern common in Indians Existing cardiovascular disease or high cardiac risk a topic we cover in depth in Part 8: GLP-1, Heart and Kidney Benefits Chronic kidney disease, where GLP-1 drugs have shown protective signals [7] A need to avoid hypoglycemia or further weight gain, which older drugs like sulfonylureas often cause DPP-4 inhibitors such as teneligliptin, sitagliptin, vildagliptin, and linagliptin are widely prescribed in India and lower blood glucose with a low risk of hypoglycemia
The roles of CBS and CSE in neoangiogenesis have been shown for different cancer types, and possibly involve per-sulphidation of KATP channels and the activation of MAPK signalling pathways, 156,157,158,159,160 which have been demonstrated in endothelial cells
